Professor Gareth Veal
| A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) | 2024 |
|
Dr Hayden Bell Dr Helen Blair Samantha Jepson Gosling Dr Martin Galler Dan Astley et al. | Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia | 2024 |
|
Professor Gareth Veal Philip Berry
| Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma | 2024 |
|
Professor Gareth Veal
| The use of sodium thiosulfate as an otoprotectant in cancer patients treated with platinum compounds: a review of the literature | 2024 |
|
Professor Gareth Veal Dr Shelby Barnett
| Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom | 2024 |
|
Professor Gareth Veal
| A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer | 2023 |
|
Julieann Sludden Professor Gareth Veal Professor Ruth Plummer
| A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma | 2023 |
|
Professor Gareth Veal Professor Steve Wedge Dr Christopher Bacon Professor Philip Sloan Professor Alastair Greystoke et al. | A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer | 2023 |
|
Professor Gareth Veal
| Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials | 2023 |
|
Dr Shelby Barnett Dr Martin Galler Dr David Jamieson Professor Gareth Veal
| Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report | 2023 |
|
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal
| Generation of evidence-based carboplatin dosing guidelines for neonates and infants | 2023 |
|
Dr Shelby Barnett Professor Gareth Veal
| Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk | 2023 |
|
Professor Gareth Veal
| Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial | 2023 |
|
Julie Errington Dr Shelby Barnett Professor Gareth Veal
| Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma | 2023 |
|
Dr Shelby Barnett Professor Gareth Veal
| A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children | 2022 |
|
Dr Shelby Barnett Dr Vickyanne Carruthers Professor Deborah Tweddle Professor Gareth Veal
| Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance | 2022 |
|
Dr Vickyanne Carruthers Dr Shelby Barnett Dr Tasnim Arif Professor Gareth Veal
| Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series | 2022 |
|
Dr Oladipo Idowu Professor Gareth Veal Dr David Jamieson
| Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum | 2022 |
|
Dr Shelby Barnett Professor Gareth Veal
| Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations | 2022 |
|
Professor Gareth Veal
| Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04) | 2022 |
|
Dr Tobias Menne Professor Julie Irving Professor Ruth Plummer Dr Geoff Shenton Professor Gareth Veal et al. | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial | 2022 |
|
Dr Shelby Barnett Professor Deborah Tweddle Professor Gareth Veal
| Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients | 2022 |
|
Melanie Griffin Dr Claire Jennings Professor Gareth Veal
| Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia | 2021 |
|
Dr Catherine Gowland Philip Berry Julie Errington Professor Gareth Veal
| Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study | 2021 |
|
Dr Shelby Barnett Professor Gareth Veal
| Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom | 2021 |
|
Dr Shelby Barnett Julie Errington Julieann Sludden Dr David Jamieson Professor Gareth Veal et al. | Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population | 2021 |
|
Professor Gareth Veal Professor Deborah Tweddle Julie Errington
| Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial | 2021 |
|
Eve Roberts Dr Jasper Mogg Professor Gareth Veal
| Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective | 2020 |
|
Dr Karen Barker Philip Berry Professor Gareth Veal Dr John Anderson
| In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis | 2019 |
|
Suriyon Uitrakul Dr Claire Hutton Professor Gareth Veal Dr David Jamieson
| A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells | 2019 |
|
Dr Marina Danilenko Dr Kirsty Hodgson Monique Zangarini Professor Gareth Veal Professor Neil Rajan et al. | Diverse assays from a single skin punch biopsy to assess topical drug intervention | 2019 |
|
Professor Gareth Veal
| Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function | 2019 |
|
Liz Matheson Huw Thomas Marian Case Dr Helen Blair Rosanna Jackson et al. | Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM | 2019 |
|
Dr Rosanna Jackson Philip Berry Julie Errington Professor Julie Irving Professor Gareth Veal et al. | Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial | 2019 |
|
Professor Gareth Veal Philip Berry
| Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste | 2019 |
|
Professor Gareth Veal Dr Edward Amankwatia
| Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities | 2019 |
|
Professor Gareth Veal
| Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition | 2019 |
|
Professor Gareth Veal Julie Errington
| Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function | 2019 |
|
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Calum Kirk Dr Katrina Wood et al. | Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma | 2019 |
|
Professor Gareth Veal Julie Errington Dr Leigh McDonald Professor Deborah Tweddle
| The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression | 2019 |
|
Professor Ruth Plummer Professor Steve Wedge Professor Gareth Veal
| A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours | 2018 |
|
Professor Gareth Veal
| Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence | 2018 |
|
Professor Gareth Veal
| Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss | 2018 |
|
Dr Marina Danilenko Elaine Stamp Dr Deborah Stocken Monique Zangarini Amy Cranston et al. | Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib | 2018 |
|
Monique Zangarini Philip Berry Professor Gareth Veal
| Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts | 2018 |
|
Dr Lynsey McKenzie Hasan Issa Sandeep Potluri Dr Helen Blair Asmida Isa et al. | The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation | 2018 |
|
Professor Gareth Veal
| The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients | 2018 |
|
Professor Gareth Veal
| Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report | 2018 |
|
Dr Britta Vormoor Professor Gareth Veal Melanie Griffin Professor Julie Irving Lynne Minto et al. | A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia | 2017 |
|
Monique Zangarini Philip Berry Julieann Sludden Professor Gareth Veal
| Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma | 2017 |
|
Monique Zangarini Professor Neil Rajan Dr Marina Danilenko Philip Berry Professor Gareth Veal et al. | Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors | 2017 |
|
Professor Gareth Veal Dr David Jamieson Katja Kuver
| Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial | 2017 |
|
Dr Lindi Chen Philip Berry Dr Jennifer Bonner Dr Katrina Wood Professor Gareth Veal et al. | In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma | 2017 |
|
Professor Gareth Veal Carine Boue Charlotte Lecour Annette Otto Maryam Rastegari et al. | Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey | 2017 |
|
Professor Gareth Veal Julie Errington
| Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens | 2016 |
|
Professor Gareth Veal Julieann Sludden Dr David Jamieson Julie Errington Dr Ghada Malik et al. | Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma | 2016 |
|
Chris Walsh Dr Jennifer Bonner Professor Alan Boddy Professor Gareth Veal
| Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer | 2016 |
|
Julie Errington Dr Ghada Malik Lisa Price Professor Gareth Veal
| Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK | 2016 |
|
Rosanna Jackson Professor Julie Irving Professor Gareth Veal
| Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia | 2016 |
|
Professor Gareth Veal
| Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2 | 2016 |
|
Dr Vikram Gota Professor Gareth Veal
| Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. | 2016 |
|
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle
| Carboplatin therapeutic monitoring in preterm and full-term neonates | 2015 |
|
Professor Gareth Veal Julie Errington Dr James Hayden Professor Deborah Tweddle
| Carboplatin therapeutic monitoring in preterm and full-term neonates | 2015 |
|
Professor Gareth Veal Julie Errington Professor Deborah Tweddle
| Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience | 2015 |
|
Professor Gareth Veal
| Blood volumes in paediatric clinical trials: a review of current regulations and guidance for research studies | 2014 |
|
Dr Chris Hill Julie Errington Dr Ghada Malik Professor Alan Boddy Professor Gareth Veal et al. | Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer | 2014 |
|
Professor Gareth Veal Dr Pamela Kearns
| Defining a Target Intra-Cerebrospinal Fluid Steady State Etoposide Concentration [CSF Etoposide) for Phase I Study in Children with Leptomeningeal Metastasis (LM): Intrepid, A First in Man Study | 2014 |
|
Professor Gareth Veal Dr David Walker
| Etoposide Pharmacokinetics Following Intra-Cerebrospinal Fluid Administation in Patients with Leptomeningeal Metastases | 2014 |
|
Professor Gareth Veal
| Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib | 2014 |
|
Professor Gareth Veal
| Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics | 2014 |
|
Professor Gareth Veal
| Review of therapeutic drug monitoring of anticancer drugs part 2 – Targeted therapies | 2014 |
|
Professor Gareth Veal
| Therapeutic drug monitoring in cancer – Are we missing a trick? | 2014 |
|
Professor Gareth Veal Julie Errington Sophie Rowbotham Nicola Illingworth Dr Ghada Malik et al. | Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma | 2013 |
|
Christopher Hill Dr David Jamieson Huw Thomas Dr Colin Brown Professor Alan Boddy et al. | Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo | 2013 |
|
Professor Gareth Veal Julie Errington Dr Ghada Malik Dr Chris Hill Professor Alan Boddy et al. | Investigating the pharmacokinetics and dosing of anticancer drugs in infants and young children | 2013 |
|
Professor Gareth Veal
| Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial | 2012 |
|
Professor Gareth Veal Professor Alan Boddy
| Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring | 2012 |
|
Professor Gareth Veal Professor Alan Boddy
| Chemotherapy in newborns and preterm babies | 2012 |
|
Professor Isabella Orienti Professor Gareth Veal
| Novel micelles based on amphiphilic branched PEG as carriers for fenretinide | 2012 |
|
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick
| Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold | 2012 |
|
Professor Ann Daly Professor Gareth Veal Dr David Jamieson Dr Sally Coulthard
| Pharmacogenomics research at Newcastle University | 2012 |
|
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick
| Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates | 2012 |
|
Dr Jane Renwick Shaun Martin Nicola Illingworth Dr David Jamieson Professor Penny Lovat et al. | The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide | 2012 |
|
Dr Emma Meczes Huw Thomas Professor Richard Edmondson Professor Gareth Veal Professor Alan Boddy et al. | Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours | 2012 |
|
Professor Alan Boddy Professor Ann Daly Professor Gareth Veal
| Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases | 2011 |
|
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole
| Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy | 2011 |
|
Julie Errington Professor Alan Boddy Professor Gareth Veal Mike Cole
| Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients | 2011 |
|
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick
| Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates | 2011 |
|
Dr Caroline Bridgens Professor Gareth Veal Dr Chris Redfern Dr Jane Renwick
| Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26) | 2011 |
|
Professor Gareth Veal
| Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines | 2010 |
|
Professor Gareth Veal
| Clinical pharmacology in the adolescent oncology patient | 2010 |
|
Mike Cole Professor Alan Boddy Professor Gareth Veal
| Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate | 2010 |
|
Bertrand Girard Professor Gareth Veal
| Oxazaphosphorines: New therapeutic strategies for an old class of drugs | 2010 |
|
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy
| Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients | 2010 |
|
Dr Jane Renwick Dr Ross Flockhart Professor Gareth Veal Professor Penny Lovat Dr Chris Redfern et al. | Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells | 2010 |
|
Sophie Rowbotham Professor Alan Boddy Dr Chris Redfern Professor Gareth Veal Professor Ann Daly et al. | Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation | 2010 |
|
Sophie Rowbotham Professor Ann Daly Professor Gareth Veal Professor Alan Boddy
| Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans | 2010 |
|
Dr Malcolm Coulthard Mike Cole Professor Gareth Veal Dr Michael Keir
| Human renal function maturation: a quantitative description using weight and postmenstrual age | 2009 |
|
Julie Errington Professor Alan Boddy Professor Gareth Veal
| Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma | 2009 |
|
Mike Cole Professor Alan Boddy Dr Michael Keir Professor Gareth Veal
| Estimation of renal function and its potential impact on carboplatin dosing in children with cancer | 2008 |
|
Dr Jane Renwick Professor Gareth Veal Dr Chris Redfern
| Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells | 2008 |
|
Professor Gareth Veal Professor Alan Boddy
| Population pharmacokinetic investigation of actinomycin D in children and young adults | 2008 |
|
Mike Cole Annie Parry Dr Michael Reid Professor Alan Boddy Professor Gareth Veal et al. | A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer | 2007 |
|
Professor Gareth Veal Julie Errington Dr Michael Tilby Professor Alan Boddy
| Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours | 2007 |
|
Professor Alan Boddy Melanie Griffin Julie Errington Professor Gareth Veal
| Dosing of cancer patients with low or absent renal function | 2007 |
|
Dr Michael Keir Mike Cole Annie Parry Professor Alan Boddy Professor Gareth Veal et al. | Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing | 2007 |
|
Dr Jane Renwick Gordon Taylor Huw Thomas Professor Alan Boddy Dr Chris Redfern et al. | Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo | 2007 |
|
Professor Gareth Veal Mike Cole Geoffrey Taylor Julie Errington Professor Alan Boddy et al. | Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients | 2007 |
|
Professor Gareth Veal Mike Cole Julie Errington Professor Alan Boddy
| Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group | 2007 |
|
Professor Gareth Veal Sophie Rowbotham Professor Alan Boddy
| Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma | 2007 |
|
Dr Jane Renwick Professor Gareth Veal Dr Chris Redfern Professor Penny Lovat
| Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours | 2007 |
|
Professor Gareth Veal Julie Errington Huw Thomas Professor Alan Boddy
| Biliary excretion of etoposide in children with cancer | 2006 |
|
Professor Gareth Veal
| Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11 | 2006 |
|
Mike Cole Professor Alan Boddy Dr Pamela Kearns Lisa Price Annie Parry et al. | Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know? | 2006 |
|
Dr Jane Renwick Dr Chris Redfern Professor Gareth Veal
| 13-cis Retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success? | 2005 |
|
Dr Jane Renwick Professor Alan Boddy Dr Chris Redfern Professor Andrew Pearson Professor Gareth Veal et al. | Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells | 2005 |
|
Professor Gareth Veal Mike Cole Julie Errington Annie Parry Dr Juliet Hale et al. | Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study | 2005 |
|
Professor Gareth Veal Dr Michael Tilby
| A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia | 2004 |
|
Mike Cole Annie Parry Dr Michael Keir Professor Andrew Pearson Professor Alan Boddy et al. | Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics | 2004 |
|
Professor Gareth Veal Professor Alan Boddy
| Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy | 2004 |
|
Professor Gareth Veal Dr Sally Coulthard Professor Alan Boddy
| Chemotherapy individualization | 2003 |
|
Professor Gareth Veal
| Clinical and cellular pharmacology in relation to solid tumours of childhood | 2003 |
|
Professor Gareth Veal Julie Errington Julieann Sludden Melanie Griffin Annie Parry et al. | Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry | 2003 |
|
Julie Errington Professor Gareth Veal Julieann Sludden Melanie Griffin Professor Andrew Pearson et al. | Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry | 2003 |
|
Justin Armstrong Professor Gareth Veal Dr Chris Redfern Professor Alan Boddy
| Effects of ketoconazole and acitretin on retinoid isomerisation and metabolism in neuroblastoma | 2003 |
|
Professor Gareth Veal Julie Errington Professor Andrew Pearson Professor Alan Boddy
| Poster Presentation: Oxidative metabolism of 13-cis-retinoic acid in children with neuroblastoma | 2003 |
|
Dr Birju Rana Professor Gareth Veal Professor Andrew Pearson Dr Chris Redfern
| Retinoid X receptors and retinoid response in neuroblastoma cells | 2002 |
|
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al. | Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells | 2002 |
|
Dr Birju Rana Professor Gareth Veal Professor Andrew Pearson Dr Chris Redfern
| Retinoid X receptors and retinoid response in neuroblastoma cells | 2002 |
|
Professor Gareth Veal Melanie Griffin Annie Parry Dr Juliet Hale Professor Andrew Pearson et al. | A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin | 2001 |
|
Professor Gareth Veal Dr Cinera Dias Annie Parry Julie Errington Dr Juliet Hale et al. | Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy | 2001 |
|
Professor Gareth Veal Julie Errington Dr Chris Redfern Professor Andrew Pearson Professor Alan Boddy et al. | Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma | 2001 |
|
Professor Gareth Veal Dr Cinera Dias Professor Alan Boddy Annie Parry Dr Juliet Hale et al. | In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children | 2000 |
|
Professor Gareth Veal Professor Alan Boddy Huw Thomas Annie Parry Professor Andrew Pearson et al. | Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy | 1999 |
|
Professor Gareth Veal
| Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro | 1998 |
|